The future of the global pharmaceutical industry is certain to be dynamic and highly responsive to marketing and regulatory forces. Expectations for efficient and effective manufacturing facilities is also rising in response to requirements for flexibility, safety value and speed to market. Conforming and performing to the many economic and regulatory requirements is clearly the manufacturing objective of the future.

Pharmaceutical manufacturing facilities are complicated and occupy an increasing share of an enterprise`s strategic horizon. The total life cycle of events to deliver a pharmaceutical facility typically includes traditional elements of planning, design, construction, qualification, validation and operation.

The need to meet the current GMP regulations is therefore paramount in the pharmaceutical industries. Facilities that effectively incorporate the GMP requirements are easily licensed and thus bring the project on stream in a timely fashion. The incorporation of the GMP requirements into Good design practises (GDP) at the onset of the project ensures that this aspect of regulatory requirements is met.

For this session, we have gathered many high-level industry experts together to provide insights and unique solutions for the most common challenges faced within the industry today.

Attendees / presentations:

• Schmidhalter // Lonza // Presentation
• Kundig // Meddiscovery // Presentation
• Lawny&Coquoz // Triskel // Presentation
• Baud-Grasset // OM Pharma // Presentation

This BioStart is organized in association with Eclosion, Sciences de la vie and the Executive MBA in "Management of Technology" (MoT) EPFL-HEC Lausanne 

˹

Dubuis, 11.08.2009

˻